Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31686029 | 1.00 | ALDH1A1 (0.52) | ALDH1A1HPGDMGLLGABRA1GABRB2 | |
| SCHEMBL29809738 | 0.87 | ALDH1A1 (0.56) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1945874 | 0.87 | ALDH1A1 (0.56) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL7781555 | 0.82 | ALDH1A1 (0.44) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| Water SCHEMBL5700740 | 0.82 | GABRA1 (0.55) | ALDH1A1MGLLGABRA1GABRB2CYP2D6 | |
| SCHEMBL8763318 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| Cyanate SCHEMBL28199832 | 0.80 | GABRA1 (0.50) | ALDH1A1HPGDMGLLGABRA1GABRB2 | |
| SCHEMBL8592198 | 0.80 | L3MBTL1 (0.49) | ALDH1A1HPGDMAPTNPSR1L3MBTL1 | |
| Nitrogen SCHEMBL27542451 | 0.79 | GABRA1 (0.52) | ALDH1A1MGLLGABRA1GABRB2CYP2D6 | |
| SCHEMBL25425763 | 0.79 | GABRA1 (0.58) | ALDH1A1MGLLGABRA1GABRB2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023205458-A2 | FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3943500-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | Agilent Technologies, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2022-01-06 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-10196418-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-9458118-B2 | Sodium channel modulators for the treatment of pain and diabetes | CHROMOCELL CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160221974-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-05-12 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| CN-1715301-A | Catalyst component for olefin polymerization reaction and its catalyst | CHINA PETROCHEMICAL CORP (CN) | 2006-01-04 | — | — | CN | disclosed |
| EP-0949247-B1 | Process for the preparation of piperidinylidene derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-6008358-A | Process for the preparation of piperidinylidene derivative | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0949247-A1 | Process for the preparation of piperidinylidene derivatives | Takasago International Corporation (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-4460604-A | ANALGESICS, NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1984-07-17 | — | — | US | disclosed |
| US-4180584-A | ANALGESIC; NARCOTIC ANTAGONIST | THE UPJOHN COMPANY (US) | 1979-12-25 | — | — | US | disclosed |
| US-4136156-A | HYDROGEN CYANIDE, HYDROGENATION CATALYSTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-01-23 | — | — | US | disclosed |
| US-4065573-A | ANALGESICS | THE UPJOHN COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-3979444-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES | THE UPJOHN COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221974-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | SCN7A, SCN1A, SCN10A | ALDH1A1 2045/4885HPGD 1212/4885MGLL 2366/4885 |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | SCN7A, SCN1A, SCN10A | ALDH1A1 2045/4885HPGD 1212/4885MGLL 2366/4885 |
| US-10196418-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | ALDH1A1 3878/4885HPGD 2164/4885MGLL 3873/4885 |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | ALDH1A1 3878/4885HPGD 2164/4885MGLL 3873/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | ALDH1A1 2178/4885HPGD 3894/4885MGLL 2220/4885 |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | ALDH1A1 1577/4885HPGD 2042/4885MGLL 4470/4885 |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | ALDH1A1 3878/4885HPGD 2164/4885MGLL 3873/4885 |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | SCN7A, SCN1A, SCN1B | ALDH1A1 1261/4885HPGD 2375/4885MGLL 4395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.